Z-103 Phase III Clinical Study in patients with Taste Disorder - A placebo-controlled superiority study -

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221862

Enrollment

260

Registered

2012-07-23

Start date

2012-07-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

taste disorders induced by zinc-deficiency

Interventions

investigational material(s) Generic name etc : Z-103 INN of investigational material : Polaprezinc Therapeutic category code : 322 Mineral preparations Dosage and Administration for Investigational ma

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with the following three types. 1. Zinc-deficient taste disorder 2. Idiopathic taste disorder 3. Drug-induced taste disorder (with some exceptions)

Exclusion criteria

Exclusion criteria: 1. Central nervous system disorder 2. Peripheral neuropathy 3. Intraoral defect and salivary gland disorder 4. Psychiatric disorder 5. Systemic disorders that cause taste disorder

Design outcomes

Primary

Measure	Time frame
Final overall efficacy evaluation Filter-paper Disk Method	—

Secondary

Measure	Time frame
Efficacy evaluation at each evaluation period Filter-paper Disk Method	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026